The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / NSAIDs: The Heart of the Controversy

NSAIDs: The Heart of the Controversy

June 1, 2007 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

And narcotics—be sure that you use lots of those, To treat inflammation in fingers and toes. Reduction in swelling? The joints might not show it, But your patient will be too obtunded to know it!”

You Might Also Like
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • Are NSAIDS Even Less Safe Than We Thought?
Explore This Issue
June 2007
Also By This Author
  • Rheumatology Chooses Wisely

So how should we deal with this unsought advice? Should we fuss and protest or instead just make nice? Should our own guidelines undergo major revision, Or should we instead merely laugh in derision?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

We might instead say, “Cardiology friends, It seems that our specialties could make amends, If you, notwithstanding the size of your fees, Acknowledged some limits of your expertise,

And saw that when treating arthritic disease Rheumatology input is critical, please!”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Fox is chief of rheumatology at the University of Michigan in Ann Arbor.

ACR Speaks Out: Comments from the College

The AHA recently issued a position statement on the use of NSAIDs.1 While this statement provides a useful overview of the published studies relating to cardiovascular risk associated with both the selective and non-selective COX inhibitor NSAIDs, the position statement suggests a treatment strategy for arthritis pain that is not based on solid evidence or clinical judgment.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

As the current president and members of the Drug Safety Committee of the ACR, we feel that the “stepped-care approach to management of musculoskeletal symptoms” in this article oversimplifies the management of patients with rheumatic diseases. In many acute and chronic musculoskeletal disorders, the pathophysiologic underpinnings are a direct result of inflammation. NSAIDs have been shown to specifically suppress the inflammatory process and provide excellent relief in many painful rheumatic conditions in both experimental and clinical studies. These agents improve symptoms and minimize tissue complications associated with progression of inflammatory processes.

Randomized placebo and active controlled clinical trials have established the efficacy of NSAIDs over and above many other analgesic agents. Moreover, to be effective in suppressing the inflammatory process, these NSAIDS need to be used in the pharmacologic doses and dosing duration found to suppress the COX mediated inflammatory process. RA, the spondyloarthropathies, psoriatic arthritis, and osteoarthritis have been shown to cause early death, chronic disability, and a significant negative effect on overall quality of life.2

While we appreciate the documented cardiovascular toxicity associated with selective and non-selective NSAIDs, the current AHA statement does not reflect the proven benefits of these agents in patients with arthritis and other chronic inflammatory conditions. Sufficient treatment options are critical for patients with arthritis. Just as collaborative treatment plans for a given patient result in improved care, we urge the cardiology community to engage their rheumatology colleagues in formulating optimal recommendations for the use of NSAIDs.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Analgesics, Drug Updates, Safety Tagged With: AC&R, dosage, Nonsteroidal anti-inflammatory drugs (NSAIDs), patient care, rheumatologist, Safety, side effectIssue: June 2007

You Might Also Like:
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • Are NSAIDS Even Less Safe Than We Thought?
  • Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.